Janssen Files NDA for Esketamine Nasal Spray to the US for treatment-resistant depression

 Janssen Files NDA for Esketamine Nasal Spray to the US for treatment-resistant depression

Janssen Files NDA for Esketamine Nasal Spray to the US for treatment-resistant depression

Shots:
  • This NDA is on basis of five pivotal studies: three short-term, one withdrawal maintenance of effect and one long-term safety, assessing (esketamine spray + a newly initiated oral antidepressant vs PBO nasal spray + newly initiated antidepressant)
  • Results: reduction in depressive symptoms, delayed time to relapse symptoms of depression, better tolerance with no new safety signals
  • Janssen aims to file MAA for Esketamine Nasal Spray to EMA for the treatment-resistant depression in H2’18. Esketamine also received from FDA BT designation for treatment-resistant depression
Click here to read full press release/ article | Ref: Johnson & Johnson | Image:  Pharma Board

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post